ESR1 and cancer: More importantly, current ongoing cytoprotective responses of multiple cancer types to the CGs therapies in vitro have been noticed (Sun et al., 2018) that have forced us to elaborate with deep mechanistic study in both ER-positive and ER-negative breast cancer cells.